VEGF Pathway

• Background
• VEGF Pathway
  • Ligands
  • Receptors
• VEGF – Signal Transduction
• Factors Regulating VEGF and VEGFR Expression
• VEGFR in Human Diseases
• Conclusion

Background

Formation of new blood vessels, a process known as angiogenesis, is a fundamental biological process required for embryonic development, tissue repair, ovulation and menstruation. Angiogenesis involves sprouting of new blood vessels from the existing blood vessels through the proliferation, migration and invasion of endothelial cells. This process is tightly regulated by pro- and anti-angiogenic factors, dysregulation of which can lead to abnormal vasculature. Several signaling mechanisms function to form new blood vessels, including vascular endothelial growth factors (VEGFs)/VEGFRs, angiopoietin/Tie receptors¹, Platelet-derived growth factors (PDGFs)/PDGFRs² and EphirinB2/EphirinB4³ . Among these, VEGF signaling has been often recognized as the key regulator of angiogenesis.

VEGF and VEGF Receptors

Vascular permeability factor (VPF) was initially known to show hyperpermeability of tumor blood vessels and involved in formation of tumor-associated ascites⁴. Later, studies revealed vascular endothelial growth factors (VEGF) as an angiogenic growth factor displaying high specificity for endothelial cells⁵. Subsequently, it was discovered that both VEGF and VPF are encoded by a single VEGF gene and are products of alternate splicing. Analysis of VEGF/VPF cDNA clones also revealed significant homology to platelet-derived growth factor (PDGF).

Ligands

There are five structurally related VEGF ligands: VEGFA, VEGFB, VEGFC, VEGFD and Placenta Growth Factor (PIGF). All the VEGFs are homodimers with disulphide bonds. The native VEGF is heparin-binding homodimeric glycoprotein closely corresponds to the VEGF165 variant. VEGFA was shown to have five isoforms with 121, 145, 165, 189 and 206 amino acids as a result of alternate splicing⁶. VEGF ligands are secreted by various cell types and act in an autocrine and paracrine manner. Each VEGF ligand binds differently to the receptors and induces distinct biological responses⁷.

Receptors

VEGF ligands bind to three receptor tyrosine kinases, VEGFR1 (Flt-1), VEGFR2 (Flk-1, KDR) and VEGFR3 and to co-receptors like Neuropilin 1 (NRP1). While VEGF receptors have homology in kinase domains their signaling cascade differs significantly. Ligand binding induces receptor dimerization (homo/hetero dimers) and activation of the kinase domain.

Phylogenetic analyses revealed that D-VEGFR/PVR, found in Drosophila melanogaster is the common ancestor of the vertebrate VEGF receptors. Both VEGFR and PDGFR in vertebrates were most likely obtained from the duplication/triplication of single D-VEGFR/PVR gene^8,9.

Product No.	V7259	V4512	SRP4363	SRP4364	SRP4365	V5765	SRP3182	H9166
Product	VEGF	VEGF	VEGF165	VEGF165	VEGF165	VEGF165	VEGF	VEGF165
Species	Human	Mouse	Human	Mouse	Rat	Human	Human	Human
Expressed in	E. coli	E. coli	E. coli	E. coli	E. coli	HEK	E. coli	HEK
Endotoxin-tested	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Carrier-free	No	No	No	No	No	No	Yes	Yes
Purity	≥98%	≥98%	≥98%	≥98%	≥98%	≥95%	≥98%	≥95%
ED50/EC50	1-10 ng/mL	1-10 ng/mL	≤0.1 ng per ug	≤0.1 ng per mg	≤0.1 ng per ug	≤10 ng/mL	1.0-8.0 ng/mL	2-10 ng/mL

VEGF – Signal Transduction

VEGF signaling involves the cascade of signals triggered when the ligand binds the VEGF receptors. The downstream signaling includes activation of phospholipase Cγ1, MAPK pathway via Ras/Raf1 activation and PI3K/Akt pathway. Phospholipase Cγ1 regulates the concentration of intracellular Ca⁺² ions and formation of endothelial nitric oxide synthase. The effect of all the cascades provides a balance of pro- and anti-angiogenic signals that maintain the vasculature and/or result in sprouting of new blood vessels, cell proliferation and cell migration (Figure 1). Table 1 summarizes signaling transduction through VEGF receptors.

Table 1. Signaling transduction by VEGF receptors

Receptor	VEGFR1	VEGFR2	VEGFR3	NRP1
Ligands	VEGFA, VEGFB, PIGF	VEGFA, VEGFC, VEGFD	VEGFC, VEGFD	VEGF165, PlGF
Cell Expression	Endothelial, Dendritic, Monocytes/ Macrophages, Osteoblasts, Pericytes, Trophoblasts	Endothelial, Neuronal, Retinal progenitors, hematopoietic stem cells,  Osteoblasts, Megakaryocytes	Lymphatic endothelial cells, Monocytes/Macrophages	Endothelial, Neuronal, Plasmacytoid Dendritic cells
Signal Transduction	Activation of phospholipase C-γ1; regulation MAPK pathway10,11	Activation of PI3K/Akt pathway, BAD, FKHR1, Caspase1, Bcl-2	Activation of ERK and PI3K/Akt pathways	Activation of MAPK pathway
Functions	Inhibition of angiogenesis and recruitment of immune cells	Angiogenesis; cell survival, proliferation, migration, vascular permeability and inhibition of apoptosis	Lymphangiogenesis; development of vasculature; migration of endothelial cells	Vascular development; apoptosis inhibition; migration

Figure 1. VEGF Pathway

Factors Regulating VEGF and VEGFR Expression

There are several factors regulating the expression of VEGF and VEGFR. They are broadly classified into external factors, transcription factors and oncogenes. External factors such as hypoxia in tissue microenvironment regulate VEGF expression through Hypoxia Inducible Factor-1 alpha (HIF-1α)¹². Under hypoxic conditions HIF-1α dimerizes with HIF-1β, binds to the VEGF promoter inducing VEGF transcription. Growth factors and cytokines secreted in tissue microenvironment such as epidermal growth factor receptors (ErbB1 and ErbB2), insulin like growth factor-I receptor (IGF-IR)¹³, hepatocyte growth factors¹⁴, platelet-derived growth factors (PDGF)¹⁵ and cyclooxygenases (COX)¹⁶ induce angiogenesis. Oncogenes and tumor suppressors such as like c-SRC (proto-oncogene)¹⁷, BCR-ABL¹⁸, Ras¹⁹, p53²⁰ and PTEN²¹ also regulate the expression of VEGF.

VEGFR in Human Diseases

Diseases that are associated with vascular abnormalities are related to anomalies in VEGF/VEGFR signaling axis. Anti-VEGF treatment is being employed to treat certain type of cancers, and condition like preeclampsia, macular degeneration and amyotrophic lateral sclerosis.^22-28 The efficacy of antiangiogenic therapy for tumors is often met with challenges such as drug resistance and factors such as increased expression of HIF-1alpha which leads to increase in the number of cancer stem cells in the tumor niche.

Conclusion

The role of VEGF and VEGFRs is well recognized in angiogenesis and has been implicated in chronic disease conditions. Despite the development of small molecules and antibodies that suppress angiogenesis, several tumors showed resistance to anti-VEGF therapy due to parallel angiogenesis signals from other growth factors. Factors that contribute to tumor resistance and angiogenesis are yet to be extensively defined.

References

1. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, et al. 1996. Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning. Cell. 87(7):1161-1169. https://doi.org/10.1016/s0092-8674(00)81812-7

2. Heldin C, Westermark B. 1999. Mechanism of Action and In Vivo Role of Platelet-Derived Growth Factor. Physiological Reviews. 79(4):1283-1316. https://doi.org/10.1152/physrev.1999.79.4.1283

3. Wang HU, Chen Z, Anderson DJ. 1998. Molecular Distinction and Angiogenic Interaction between Embryonic Arteries and Veins Revealed by ephrin-B2 and Its Receptor Eph-B4. Cell. 93(5):741-753. https://doi.org/10.1016/s0092-8674(00)81436-1

4. Senger D, Galli S, Dvorak A, Perruzzi C, Harvey V, Dvorak H. 1983. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 219(4587):983-985. https://doi.org/10.1126/science.6823562

5. Leung D, Cachianes G, Kuang W, Goeddel D, Ferrara N. 1989. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246(4935):1306-1309. https://doi.org/10.1126/science.2479986

6. Ferrara N. 1999. Vascular Endothelial Growth Factor: Molecular and Biological Aspects.1-30. https://doi.org/10.1007/978-3-642-59953-8_1

7. Ferrara N. 2000. Vascular endothelial growth factor and the regulation of angiogenesis. Recent progress in hormone research. 55 15.

8. Ishimaru S, Ueda R, Hinohara Y, Ohtani M, Hanafusa H. 2004. PVR plays a critical role via JNK activation in thorax closure during Drosophila metamorphosis. EMBO J. 23(20):3984-3994. https://doi.org/10.1038/sj.emboj.7600417

9. Cho NK, Keyes L, Johnson E, Heller J, Ryner L, Karim F, Krasnow MA. 2002. Developmental Control of Blood Cell Migration by the Drosophila VEGF Pathway. Cell. 108(6):865-876. https://doi.org/10.1016/s0092-8674(02)00676-1

10. Sawano A, Takahashi T, Yamaguchi S, Shibuya M. 1997. The Phosphorylated 1169-Tyrosine Containing Region of Flt-1 Kinase (VEGFR-1) Is a Major Binding Site for PLC?. Biochemical and Biophysical Research Communications. 238(2):487-491. https://doi.org/10.1006/bbrc.1997.7327

11. Landgren E, Schiller P, Cao Y, Claesson-Welsh L. 1998. Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-? and migration of endothelial cells expressing Flt 1. Oncogene. 16(3):359-367. https://doi.org/10.1038/sj.onc.1201545

12. Iliopoulos O, Levy AP, Jiang C, Kaelin WG, Goldberg MA. 1996. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.. Proceedings of the National Academy of Sciences. 93(20):10595-10599. https://doi.org/10.1073/pnas.93.20.10595

13. Reinmuth N, Fan F, Liu W, Parikh AA, Stoeltzing O, Jung YD, Bucana CD, Radinsky R, Gallick GE, Ellis LM. 2002. Impact of Insulin-Like Growth Factor Receptor-I Function on Angiogenesis, Growth, and Metastasis of Colon Cancer. Lab Invest. 82(10):1377-1389. https://doi.org/10.1097/01.lab.0000032411.41603.c2

14. Van Belle E, Witzenbichler B, Chen D, Silver M, Chang L, Schwall R, Isner JM. 1998. Potentiated Angiogenic Effect of Scatter Factor/Hepatocyte Growth Factor via Induction of Vascular Endothelial Growth Factor. Circulation. 97(4):381-390. https://doi.org/10.1161/01.cir.97.4.381

15. Dong J, Grunstein J, Tejada M, Peale F, Frantz G, Liang W, Bai W, Yu L, Kowalski J, Liang X, et al. 2004. VEGF-null cells require PDGFR ? signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J. 23(14):2800-2810. https://doi.org/10.1038/sj.emboj.7600289

16. Needleman P, Truk J, Jakschik BA, Morrison AR, Lefkowith JB. 1986. Arachidonic Acid Metabolism. Annu. Rev. Biochem.. 55(1):69-102. https://doi.org/10.1146/annurev.bi.55.070186.000441

17. Fleming R, Ellis LM, Parikh NU, Liu W, Staley CA, Gallick GE. 1997. Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by activity of src kinase. Surgery. 122(2):501-507. https://doi.org/10.1016/s0039-6060(97)90044-1

18. Dias S, Hattori K, Heissig B, Zhu Z, Wu Y, Witte L, Hicklin DJ, Tateno M, Bohlen P, Moore MAS, et al. 2001. Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proceedings of the National Academy of Sciences. 98(19):10857-10862. https://doi.org/10.1073/pnas.191117498

19. Konishi T, Huang CL, Adachi M, Taki T, Inufusa H, Kodama K, Kohno N, Miyake M. The K-ras gene regulates vascular endothelial growth factor gene expression in non-small cell lung cancers.. Int J Oncol. https://doi.org/10.3892/ijo.16.3.501

20. Fujisawa T, Watanabe J, Kamata Y, Hamano M, Hata H, Kuramoto H. 2003. Effect of p53 gene transfection on vascular endothelial growth factor expression in endometrial cancer cells. Experimental and Molecular Pathology. 74(3):276-281. https://doi.org/10.1016/s0014-4800(03)00020-0

21. Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, Gottschalk A, Ryan H, Johnson R, Jefferson A. 2000. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes & development. 4(4)pp.391-396.

22. Youssoufian H, Hicklin DJ, Rowinsky EK. 2007. Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy. Clinical Cancer Research. 13(18):5544s-5548s. https://doi.org/10.1158/1078-0432.ccr-07-1107

23. Wang T, Lockhart AC. 2012. Aflibercept in the Treatment of Metastatic Colorectal Cancer. Clin Med Insights Oncol. 6CMO.S7432. https://doi.org/10.4137/cmo.s7432

24. Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T, Takeda S, Yano T, Tsutsumi O, Taketani Y. 2003. Elevated Serum Soluble Vascular Endothelial Growth Factor Receptor 1 (sVEGFR-1) Levels in Women with Preeclampsia. The Journal of Clinical Endocrinology & Metabolism. 88(5):2348-2351. https://doi.org/10.1210/jc.2002-021942

25. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al. 2004. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. N Engl J Med. 350(23):2335-2342. https://doi.org/10.1056/nejmoa032691

26. Sun X, Yang S, Zhao J. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. DDDT.1857. https://doi.org/10.2147/dddt.s97653

27. Oosthuyse B, Moons L, Storkebaum E, Beck H, Nuyens D, Brusselmans K, Dorpe JV, Hellings P, Gorselink M, Heymans S, et al. 2001. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet. 28(2):131-138. https://doi.org/10.1038/88842

28. Verheyen A, Peeraer E, Nuydens R, Dhondt J, Poesen K, Pintelon I, Daniels A, Timmermans J, Meert T, Carmeliet P, et al. 2012. Systemic anti-vascular endothelial growth factor therapies induce a painful sensory neuropathy. 135(9):2629-2641. https://doi.org/10.1093/brain/aws145